• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

byMinjee Kim
January 26, 2022
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The primary efficacy outcome of symptomatic and asymptomatic venous thromboembolism was significantly lower in the rivaroxaban group (3.14%) compared to control (9.43%).

2. No significant difference in the primary safety outcome of major bleeding was noted.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Patients hospitalized with COVID-19 have been suggested to have an increased risk of thromboembolic events compared to the general population. Although in-hospital thromboprophylaxis is routinely given, there is no consensus on extended thromboprophylaxis after discharge. This randomized controlled trial aimed to assess the safety and efficacy of low-dose rivaroxaban in patients at increased risk of thromboembolism post-hospitalization with COVID-19. All patients received standard doses of heparin during hospitalization and were assigned to either the rivaroxaban 10 mg/day group or no-treatment group at discharge. Venous thromboembolism (VTE) risk was assigned based on the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) score. The primary safety outcome was major bleeding, while primary efficacy outcome included a composite of VTE, arterial thromboembolism (ATE), and cardiovascular death. According to results, patients in the rivaroxaban group reported fewer instances of VTE and all-cause mortality compared to the control group at 35 days after discharge.

Click to read the study in The Lancet

RELATED REPORTS

Worsening kidney function observed following SARS-CoV-2 infection in children

Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis

Direct oral anticoagulants increase bleeding risk after intracerebral hemorrhage in patients with atrial fibrillation

Relevant Reading: Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

In-depth [randomized controlled trial]: Between Oct 8, 2020, and June 29, 2021, 997 patients were assessed for eligibility across 14 centers in Brazil. Included were those hospitalized with COVID-19 for ≥3 days who were at increased risk of VTE. Altogether, 320 patients (160 each to rivaroxaban 10 mg/day and no anticoagulation group) were included in the final analysis. Mean patient age was 57.1 years (standard deviation [SD] 15.2) and the majority (n=191, 60%) were male. There was no difference with respect to major bleeding in either group. However, the primary efficacy outcome of symptomatic and asymptomatic DVT, and symptomatic, asymptomatic, and fatal PE, at day 35, was significantly less in the rivaroxaban group (n=5, 3.14%) compared to control (n=15, 9.43%; relative risk (RR) 0.33, 95% confidence interval [CI] 0.13-0.90, p=0.0293). Similarly, there were fewer instances of symptomatic and fatal VTE in the treatment group (n=1, 0.63%) versus control (n=8, 5.03%; RR 0.13, 95% CI 0.02-0.99, p=0.0487). Overall, this study suggests that thromboprophylaxis with rivaroxaban improves clinical outcomes in patients with hospitalized with COVID-19 and are at high-risk for VTEs.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: arterial thromboembolismcardiovascular deathCOVID hospitalizationCOVID hypercoagulabilityCOVID thromboembolismCOVID-19heparinhypercoagulablerivaroxabanSARS-CoV-2thromboembolismvenous thromboembolismVTE
Previous Post

Premorbid neurodegenerative disease associated with increased risk of COVID-19 infection and death

Next Post

mRNA Covid-19 vaccine remained safe and efficacious through 6 months

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Worsening kidney function observed following SARS-CoV-2 infection in children

May 23, 2025
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Hematology

Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis

May 20, 2025
Use of aspirin for primary prevention linked to increased risk of intracranial hemorrhage
Cardiology

Direct oral anticoagulants increase bleeding risk after intracerebral hemorrhage in patients with atrial fibrillation

May 2, 2025
High risk of complications, but low mortality among children with MRSA bacteremia
Infectious Disease

Hospital-onset antimicrobial resistance increased during COVID-19 pandemic

April 28, 2025
Next Post
Novel coronavirus identified from patients with pneumonia in Wuhan, China

mRNA Covid-19 vaccine remained safe and efficacious through 6 months

Intensive rehabilitation not superior to traditional therapy for arm function after stroke

Risk of dementia may be increased following incident ischemic stroke: the ARIC study

Autoantibodies may precede symptom onset in Sjögren’s Syndrome

Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.